Lessons in Discovery from Lynn Silver + Pro-con on alternatives to antibiotics

Dear All:

“Good decisions come from experience, and experience comes from bad decisions … and paying attention.”

You’ve probably heard the first part of that before, but the “… and paying attention” is my addition and reflection upon reading Lynn Silver’s most recent commentary in the Springer Series Topics in Medicinal Chemistry, edited by Jed Fisher, Marvin Miller and Shahriar Mobashery. Entitled “The Antibiotic Future,” it is a discussion of the hurdles of antibiotic discovery and a summary of Lynn’s far-ranging & pithy insights. It’s not open access so you’ll have to download yourself, but here’s the link and the abstract:

  • Cite: Silver LL. The Antibiotic Future. In: Fisher J, Miller M, Mobashery S, editors. Topics in Medicinal Chemistry. Berlin, Heidelberg: Springer Berlin Heidelberg; 2017. p. 1-37.
  • Link: https://link.springer.com/chapter/10.1007/7355_2017_24
  • Abstract: Will the future of antibacterial therapy rely on an ongoing pipeline of new small molecule, direct-acting antibacterial agents that inhibit or kill bacterial pathogens, referred to here as antibiotics? What role will these small-molecule antibiotics have in the control of the bacterial infections of the future? Although there is today increased activity in the field of new antibiotic discovery, the history of this field over the past 30 years is a history of low output. This low output of new antibiotics does not encourage confidence that they can be central to the future control of bacterial infection. This low productivity is often blamed upon financial disincentives in the pharmaceutical industry, and on regulatory difficulties. But I believe that a critical underlying reason for the dearth of novel products is the fundamental difficulty of the science, coupled with a failure to directly grapple with the key scientific challenges that prevent forward motion. The future fate of antibiotic discovery will depend upon the degree to which the rate limiting steps of discovery are fully recognized, and the discovery technology turns to overcoming these blockades.

In the paper, Lynn covers everything from alternatives to antibiotics (see also below), natural products, the problem of frequency of resistance, combinations, the question of new vs. old targets, and more. This paper is great tour of the entire area and you’ll learn something from it whether you are new to the field or an old hand.

Lynn is truly a master of this field and she has over the years written many instructive papers. Just below, I provide a list of some of my favorites from her published works. If you’re doing drug discovery and haven’t explored her writings, I strongly encourage you to take an afternoon to study them in detail. I especially recommend the 2011 paper in CMR:

Finally, and if you’re interested in non-antibiotic alternative approaches, Lynn’s comments on this area may make you want to dig further. A good place to start would be with the 3 papers below — collectively, they provide a good set of pro-con comments on the challenges of this strategy. The alternatives that seek to work in combination or as enhancers are going to be very tricky to develop and it’s important to understand the issues:

In short, knowing what has come before is the only way that I know to avoid repeating past mistakes. If you’re going to make a mistake, please make a new one … it’s much more productive! Many thanks to Lynn for sharing her insights via these publications.

Best wishes,

–jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

Updating WHO’s Bacterial Priority Pathogen List: Call for advisors

Dear All, Deadline: 15 August 2021: The World Health Organization (WHO) is seeking experts to serve as members of the Advisory Group on the Bacterial Priority Pathogen List (AG BPPL). A “Call for experts” document provides information about the advisory group and the expert profiles being sought for the group. The document also provides information on

FDA-NIAID phage workshop / Social distancing in the 1800s

Dear All, This webinar merits a standalone newsletter! If you are thinking (or working on) phage, then please mark your calendar for an FDA (CBER; Center for Biologics Evaluation and Research) workshop entitled: Science and Regulation of Bacteriophage Therapy: August 30, 2021—September 1, 2021 The purpose of the public workshop is to exchange information with the

Consultants for WHO’s SECURE, Wellcome-ICARS-Danish Gov’t AMR event

Dear All, See below my signature: A 6-month consultancy with WHO to support the the SECURE initiative, a program to assist countries in accessing and sustainably managing new and existing antibiotics needed to cope with antimicrobial resistance (AMR). There’s not much online (yet) about SECURE: the best description I can find is in the Terms of Reference

AMR preparedness: Policy insight & funding call for RNA Readiness and Response (R3)

Dear All, A view from Cambodia: “If we lose this antibiotic, there is no oral treatment left for typhoid here.” Good data drives good policy … it’s a lesson that I’ve really grown to appreciate. With this in mind, Wellcome Trust has just released a report entitled “How drug-resistant infections are undermining modern medicine –

Scroll to Top